AgenT

AgenT is pioneering a novel diagnostic approach for Alzheimer's disease, aiming to shift detection into the pre-symptomatic phase where intervention could potentially prevent or slow progression. The company's core technology is a multiomics blood test that analyzes cell-free biomarkers and applies machine learning algorithms to identify Alzheimer's pathology decades before clinical symptoms appear. This positions AgenT at the forefront of the early detection market, which is critical for the success of emerging disease-modifying therapies. If successful, its test could become a routine screening tool, fundamentally changing the Alzheimer's care pathway.

A multiomics platform combining analysis of proteins and metabolites in blood plasma (cell-free Alzheimer's biology) with machine learning algorithms to decode early disease signatures for the detection of Alzheimer's pathology.

The landscape for Alzheimer's blood tests is rapidly evolving and highly competitive. Major diagnostic companies (e.g., Quest, Labcorp) and specialized biotechs (e.g., C2N, ALZpath) are advancing assays focused primarily on phosphorylated tau (p-tau) variants. AgenT's multiomics approach is more complex and earlier-stage but aims to differentiate through a potentially more comprehensive and earlier signal.